Foster v Australian Competition and Consumer Commission
[2006] FCAFC 21
At a glance
Source factsCourt
Federal Court of Australia (Full Court)
Decision date
2006-03-10
Before
Allsop JJ
Source
Original judgment source is linked above.
Judgment (107 paragraphs)
THE COURT: 1 This is an appeal from one of some 52 orders, including declarations and injunctions, made by a single Judge of the Court. The orders were made distributively against ten respondents. The first respondent, Chaste Corporation Pty Ltd (In Liquidation) ("Chaste") had, between October 1999 and December 2001, carried on business as a manufacturer of a weight loss tablet called "TRIMit." The other corporate respondent was the third respondent, Orlawood Pty Ltd ("Orlawood") which was the sole registered shareholder in Chaste, holding that share as trustee of the Webb Family Discretionary Trust which had been established by the second respondent, Braddon Ralph Webb ("Webb"). The learned primary Judge found that Chaste had effectively been entirely controlled by Webb and the fourth respondent, the present appellant, Peter Clarence Foster ("Foster"). His Honour also found that Chaste had engaged in resale price maintenance in contravention of s 48 of the Trade Practices Act 1974 (Cth) ("the Act"). There were findings, as well, that Chaste had made misleading and deceptive representations in relation to the buy-back of TRIMit tablets from area managers appointed as distributors to whom the tablets had been sold as stock. His Honour found at [97]; 'Mr Foster, Mr Webb and/ or Orlawood were knowingly concerned in the making of the buy back guarantee representations throughout the operations of Chaste. The representations were misleading and deceptive.' 2 Further findings were made at first instance that Chaste had made representations that were misleading and deceptive about the efficacy of TRIMit and that it had been approved by the Therapeutic Goods Administration ("the TGA"). As to Foster's knowledge of, and participation in, that conduct, his Honour found at [119]; 'Mr Foster played an active part in the misrepresentations which were made as to the efficacy of TRIMit. He scripted media and newspaper releases and provided instructions in relation to media campaigns. He provided instructions to Dr D'Alton and met with him in Fiji and Vanuatu. Mr Foster and Mr Cousins consulted on the wording of the Clinical trial brochure while in Fiji and resolved to use its publication as an antidote to an article which contained very clear criticism of any efficacy representations for HCA and Chromium as weight loss aids.' 3 The third category of conduct found to have contravened Pt V of the Act comprised representations as to the genuineness of Chaste's business and the concealment of Foster's involvement in it. The following findings under this head were made between [128]-[134] of the reasons below in relation to Foster; · 'The fact that all key personnel involved in the Chaste business knew that it was being operated according to the detailed directions and for the purposes of Mr Foster. Mr Webb, Mr McMullan, Mr Cousins, Mr Cooper and Dr D'Alton each had reason to believe that Mr Foster's purposes were not in accordance with the ordinary commercial expectations of the area managers and concealed his involvement from them.